Daymark Wealth Partners LLC Has $381,000 Holdings in GSK plc (NYSE:GSK)

Daymark Wealth Partners LLC decreased its holdings in shares of GSK plc (NYSE:GSK) by 49.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 11,270 shares of the pharmaceutical company’s stock after selling 11,070 shares during the quarter. Daymark Wealth Partners LLC’s holdings in GSK were worth $381,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Eastern Bank acquired a new position in shares of GSK during the 3rd quarter worth about $26,000. ST Germain D J Co. Inc. boosted its position in GSK by 195.5% during the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 522 shares during the last quarter. Sunbelt Securities Inc. grew its stake in GSK by 73.8% in the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after purchasing an additional 302 shares in the last quarter. Concord Wealth Partners increased its position in shares of GSK by 231.8% during the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after purchasing an additional 547 shares during the last quarter. Finally, Fortitude Family Office LLC bought a new stake in shares of GSK during the 3rd quarter worth approximately $42,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and lowered their target price for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. StockNews.com lowered shares of GSK from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Finally, Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Six equities research analysts have rated the stock with a hold rating, one has issued a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $43.25.

GSK Stock Performance

NYSE GSK opened at $34.08 on Friday. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.92. The stock has a market cap of $70.63 billion, a PE ratio of 22.13, a P/E/G ratio of 1.32 and a beta of 0.63. The firm has a 50-day moving average of $33.89 and a 200-day moving average of $37.87. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Stockholders of record on Friday, November 15th were issued a dividend of $0.3928 per share. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.61%. The ex-dividend date was Friday, November 15th. This is a boost from GSK’s previous quarterly dividend of $0.38. GSK’s payout ratio is currently 96.10%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.